The Patent Finder

Adrenomed AG

10 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Oct 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 13, 2026
    The maintenance fee for Method of Modulating the Adrenomedullin (ADM) Activity of a Patient by Administering to the Patient an Anti-Adm Antibody or Fragment Thereof That Specifically Binds to Mature Human Adm (US 11,673,949) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
  • 1 fee due Mar 22, 2027
    The maintenance fee for Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition (US 9,140,696) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
  • 1 fee due Oct 5, 2027
    The maintenance fee for Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy (US 9,304,127) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

PatentTitleStatus Expires Confidence
US 9,829,494Methods of treatment using ADM antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,140,696Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,304,127Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,402,900Methods of Modulating Adrenomedullin by Administering an Anti-Adrenomedullin (ADM) Antibody
In force
 · Medium confidence
In forceMedium confidence
US 10,221,238A Method of Modulating the Activity of Adrenomedullin in a Subject in Need of Therapeutic Intervention for Organ Dysfunction or Organ Failure Associated with Adranomedullin (ADM) Activity by Administering an Anti-Adrenomedullin (ADM) Antibody or an Anti-Adm Antibody Fragment to the Subject
In force
 · Medium confidence
In forceMedium confidence
US 10,227,405Methods of Modulating the Activity of Adrenomedullin in a Subject in Need of Regulation of Fluid Balance by Administering an Anti-Adrenomedullin (ADM) Antibody or an Anti-Adm Antibody Fragment
In force
 · Medium confidence
In forceMedium confidence
US 10,800,842Anti-Adrenomedullin (ADM) Monoclonal Antibodies and Anti-Adm Monoclonal Antibody Fragments That Bind to Adrenomedullin
In force
 · Medium confidence
In forceMedium confidence
US 11,673,949Method of Modulating the Adrenomedullin (ADM) Activity of a Patient by Administering to the Patient an Anti-Adm Antibody or Fragment Thereof That Specifically Binds to Mature Human Adm
In force
 · Medium confidence
In forceMedium confidence
US 12,338,281Anti-Adrenomedullin Antibodies and Pharmaceutical Compositions Thereof
In force
 · Medium confidence
In forceMedium confidence
US 12,715,911Anti-Adrenomedullin (ADM) Antibody or Anti-Adm Antibody Fragment or Anti-Adm Non-Ig Scaffold for Use in Intervention and Therapy of Congestion in a Patient in Need Thereof
In force
 · Medium confidence
In forceMedium confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 2 abandoned · 3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited